{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:01:09Z","timestamp":1762542069136},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s10620-012-2159-7","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T03:16:55Z","timestamp":1335323815000},"page":"1604-1608","source":"Crossref","is-referenced-by-count":9,"title":["Infliximab Exerts No Direct Hepatotoxic Effect on HepG2 Cells In Vitro"],"prefix":"10.1007","volume":"57","author":[{"given":"Hilbert S.","family":"de Vries","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tineke","family":"de Heij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henie M. J.","family":"Roelofs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene H. M.","family":"te Morsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert H. M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,26]]},"reference":[{"key":"2159_CR1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"VJ Navarro","year":"2006","unstructured":"Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731\u2013739.","journal-title":"N Engl J Med"},{"key":"2159_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bpg.2009.10.011","volume":"24","author":"G Rogler","year":"2010","unstructured":"Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:157\u2013165.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2159_CR3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000320410","volume":"28","author":"OS Khokhar","year":"2010","unstructured":"Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis. 2010;28:508\u2013518.","journal-title":"Dig Dis"},{"key":"2159_CR4","unstructured":"US Food and Drug Association (2004) MedWatch safety alerts for human medical products. http:\/\/www.fda.gov\/medWatch\/safety\/2004\/remicade_DHCP_dec04.pdf . Accessed 5 April 2012"},{"key":"2159_CR5","unstructured":"Federal Drug Administration (2009) REMICADE\u00ae (infliximab) for IV Injection. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103772s5234lbl.pdf . Accessed 5 April 2012"},{"key":"2159_CR6","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1612\u20131617.","journal-title":"Ann Rheum Dis"},{"key":"2159_CR7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11739-009-0342-4","volume":"5","author":"S Mancini","year":"2010","unstructured":"Mancini S, Amorotti E, Vecchio S, et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5:193\u2013200.","journal-title":"Intern Emerg Med"},{"key":"2159_CR8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/00044011-200626110-00008","volume":"26","author":"E Ierardi","year":"2006","unstructured":"Ierardi E, Valle ND, Nacchiero MC, et al. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig. 2006;26:673\u2013676.","journal-title":"Clin Drug Investig"},{"key":"2159_CR9","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/elps.201000122","volume":"31","author":"JH Yeon","year":"2010","unstructured":"Yeon JH, Na D, Park JK. Hepatotoxicity assay using human hepatocytes trapped in microholes of a microfluidic device. Electrophoresis. 2010;31:3167\u20133174.","journal-title":"Electrophoresis"},{"key":"2159_CR10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244\u2013279.","journal-title":"Pharmacol Ther"},{"key":"2159_CR11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000024347","volume":"121","author":"AG Johansson","year":"2000","unstructured":"Johansson AG, Sundqvist T, Skogh T. IgG immune complex binding to and activation of liver cells. An in vitro study with IgG immune complexes, Kupffer cells, sinusoidal endothelial cells and hepatocytes. Int Arch Allergy Immunol. 2000;121:329\u2013336.","journal-title":"Int Arch Allergy Immunol"},{"key":"2159_CR12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","volume":"7","author":"GP Aithal","year":"2011","unstructured":"Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011;7:139\u2013150.","journal-title":"Nat Rev Rheumatol"},{"key":"2159_CR13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.104.079277","volume":"313","author":"JR Rojas","year":"2005","unstructured":"Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578\u2013585.","journal-title":"J Pharmacol Exp Ther"},{"key":"2159_CR14","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/ar1440","volume":"6","author":"C Ferraro-Peyret","year":"2004","unstructured":"Ferraro-Peyret C, Coury F, Tebib JG, et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6:R535\u2013R543.","journal-title":"Arthritis Res Ther"},{"key":"2159_CR15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2796.2003.01298.x","volume":"255","author":"F D\u2019Auria","year":"2004","unstructured":"D\u2019Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med. 2004;255:409\u2013418.","journal-title":"J Intern Med"},{"key":"2159_CR16","first-page":"G579","volume":"263","author":"P Akerman","year":"1992","unstructured":"Akerman P, Cote P, Yang SO, et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol. 1992;263:G579\u2013G585.","journal-title":"Am J Physiol"},{"key":"2159_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.510250125","volume":"25","author":"A Bruccoleri","year":"1997","unstructured":"Bruccoleri A, Gallucci R, Germolec DR, et al. Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatology. 1997;25:133\u2013141.","journal-title":"Hepatology"},{"key":"2159_CR18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/hep.23870","volume":"52","author":"ED Brennd\u00f6rfer","year":"2010","unstructured":"Brennd\u00f6rfer ED, Weiland M, Frelin L, et al. Anti-tumor necrosis factor \u03b1 treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. Hepatology. 2010;52:1553\u20131563.","journal-title":"Hepatology"},{"key":"2159_CR19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.tiv.2007.12.004","volume":"22","author":"E Petit","year":"2008","unstructured":"Petit E, Langouet S, Akhdar H, et al. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro. 2008;22:632\u2013642.","journal-title":"Toxicol In Vitro"},{"key":"2159_CR20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.cbi.2009.04.004","volume":"180","author":"J Yin","year":"2009","unstructured":"Yin J, Meng Q, Zhang G, et al. Differential methotrexate hepatotoxicity on rat hepatocytes in 2-D monolayer culture and 3-D gel entrapment culture. Chem Biol Interact. 2009;180:368\u2013375.","journal-title":"Chem Biol Interact"},{"key":"2159_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-9236(99)70119-0","volume":"65","author":"LJ Egan","year":"1999","unstructured":"Egan LJ, Sandborn WJ, Mays DC, et al. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999;65:29\u201339.","journal-title":"Clin Pharmacol Ther"},{"key":"2159_CR22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijantimicag.2008.01.022","volume":"31","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Boeree MJ, Peters WHM, et al. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int J Antimicrob Agents. 2008;31:577\u2013580.","journal-title":"Int J Antimicrob Agents"},{"key":"2159_CR23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM198304283081705","volume":"308","author":"S Zimm","year":"1983","unstructured":"Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med. 1983;308:1005\u20131009.","journal-title":"N Engl J Med"},{"key":"2159_CR24","first-page":"373","volume":"7","author":"TL Ding","year":"1979","unstructured":"Ding TL, Benet LZ. Comparative bioavailability and pharmacokinetic study of azathioprine and 6-mercaptopurine in the rhesus monkey. Drug Metab Dispos. 1979;7:373\u2013377.","journal-title":"Drug Metab Dispos"},{"key":"2159_CR25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2036.2003.01652.x","volume":"18","author":"P Deibert","year":"2003","unstructured":"Deibert P, Dilger K, Fischer C, et al. High variation of tioguanine absorption in patients with chronic active Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;18:183\u2013189.","journal-title":"Aliment Pharmacol Ther"},{"key":"2159_CR26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/j.1875-9114.1987.tb04046.x","volume":"7","author":"GL Chan","year":"1987","unstructured":"Chan GL, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy. 1987;7:165\u2013177.","journal-title":"Pharmacotherapy"},{"key":"2159_CR27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jbt.10085","volume":"17","author":"S Wilkening","year":"2003","unstructured":"Wilkening S, Bader A. Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J Biochem Mol Toxicol. 2003;17:207\u2013213.","journal-title":"J Biochem Mol Toxicol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2159-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T13:50:10Z","timestamp":1497966610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2159-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,26]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2159-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,26]]}}}